Cento, Valeria
 Distribuzione geografica
Continente #
NA - Nord America 5.524
AS - Asia 2.844
EU - Europa 1.070
SA - Sud America 610
AF - Africa 142
Continente sconosciuto - Info sul continente non disponibili 102
OC - Oceania 1
Totale 10.293
Nazione #
US - Stati Uniti d'America 5.411
SG - Singapore 1.695
CN - Cina 546
BR - Brasile 491
IT - Italia 282
VN - Vietnam 279
FI - Finlandia 186
IE - Irlanda 145
DE - Germania 101
GB - Regno Unito 66
FR - Francia 64
HK - Hong Kong 59
NG - Nigeria 59
SE - Svezia 55
CA - Canada 52
IN - India 45
AR - Argentina 42
NL - Olanda 42
BD - Bangladesh 39
ZA - Sudafrica 28
MX - Messico 27
EC - Ecuador 23
IQ - Iraq 21
JP - Giappone 20
PL - Polonia 19
RU - Federazione Russa 19
TR - Turchia 19
ID - Indonesia 18
BE - Belgio 16
ET - Etiopia 15
CL - Cile 14
CO - Colombia 14
SA - Arabia Saudita 13
UA - Ucraina 13
ES - Italia 12
MY - Malesia 12
VE - Venezuela 10
MA - Marocco 9
PA - Panama 9
PH - Filippine 8
PK - Pakistan 8
PY - Paraguay 8
KE - Kenya 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
GR - Grecia 6
JO - Giordania 6
AT - Austria 5
AZ - Azerbaigian 5
BH - Bahrain 5
DZ - Algeria 5
EG - Egitto 5
KZ - Kazakistan 5
AM - Armenia 4
CM - Camerun 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
EE - Estonia 4
IL - Israele 4
JM - Giamaica 4
LV - Lettonia 4
NP - Nepal 4
PE - Perù 4
RO - Romania 4
TN - Tunisia 4
TW - Taiwan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DK - Danimarca 3
KG - Kirghizistan 3
MD - Moldavia 3
PT - Portogallo 3
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
NI - Nicaragua 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
HT - Haiti 1
KR - Corea 1
KW - Kuwait 1
KY - Cayman, isole 1
LB - Libano 1
LU - Lussemburgo 1
MF - Saint Martin 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 10.185
Città #
Dallas 895
Singapore 675
Ashburn 596
San Jose 592
Chandler 400
The Dalles 279
Shanghai 220
Council Bluffs 206
Helsinki 185
New York 150
Dublin 144
Boardman 140
Beijing 108
Los Angeles 96
Santa Clara 91
Princeton 88
Milan 80
Ho Chi Minh City 78
Lawrence 72
Hanoi 71
Benin City 59
Hong Kong 57
Rome 41
Paris 36
São Paulo 36
Phoenix 34
Buffalo 32
Amsterdam 31
Chicago 28
Bari 27
Seattle 24
Atlanta 23
London 22
Falkenstein 20
Da Nang 18
Brooklyn 17
Johannesburg 16
Pune 16
Haiphong 15
Rio de Janeiro 15
San Francisco 15
Tokyo 15
Brussels 14
Warsaw 14
Boston 13
Munich 13
Philadelphia 13
Wilmington 13
Brasília 12
Guayaquil 12
Milwaukee 12
Montreal 12
Naples 12
Orem 12
Toronto 12
Addis Ababa 11
Charlotte 11
Ribeirão Preto 11
Denver 10
Belo Horizonte 9
Campinas 9
Houston 9
Stockholm 9
Assago 8
Baghdad 8
Miami 8
Ankara 7
Ann Arbor 7
Cagliari 7
Chennai 7
Curitiba 7
Figino 7
Frankfurt am Main 7
Guarulhos 7
Las Vegas 7
Mexico City 7
Moscow 7
Pasadena 7
Quito 7
Riverside 7
Alessandria 6
Bắc Ninh 6
Fortaleza 6
Jeddah 6
Queens 6
Salvador 6
Sorocaba 6
Washington 6
Abbeville 5
Amman 5
Baku 5
Caracas 5
Casablanca 5
Detroit 5
Dhaka 5
Durban 5
Guarujá 5
Istanbul 5
Jundiaí 5
Kuala Lumpur 5
Totale 6.236
Nome #
What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? 459
Endonasal filters for the prevention and control of respiratory allergy and infections. A multi-stakeholder assessment 363
Beyond the distance between juridic and scientific decision-making process: An evidence-based prediction algorithm for professional liability assessment in healthcare-associated infections 137
Real life experiences in HCV management in 2018 113
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 106
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs 104
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 103
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions 101
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 100
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 100
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs 98
Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 98
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 95
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy 91
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 89
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 88
Back to the future (of common respiratory viruses) 87
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures 87
Epidemiology and Resistance Profiles of Bacteria Isolated From Blood Samples in Septic Patients at Emergency Department Admission: A 6-Year Single Centre Retrospective Analysis From Northern Italy 87
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 86
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 84
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 83
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 80
CLINICAL RELEVANCE OF NEXT GENERATION SEQUENCING ON BASELINE DETECTION OF MINORITY RESISTANCE ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE INHIBITORS 79
Biotech innovations in the prevention of respiratory infectious diseases 79
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 78
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 77
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 77
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 77
BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES 75
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 75
CLINICAL RELEVANCE OF ACCURATE HCV GENOTYPE AND SUBTYPE ASSIGNMENT BY NS3/NS5A/NS5B DIRECT SEQUENCING IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS 75
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 75
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 74
Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience 74
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 74
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 74
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 74
Viral Respiratory Infections: New Tools for a Rapid Diagnosis 74
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 73
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 73
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 73
Human papillomaviruses 53 and 66: clinical aspects and genetic analysis 72
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 71
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 71
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon 71
In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract 70
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 70
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 70
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 70
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study 70
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 70
Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model 69
Clinical usefulness of HCV sequencing on clinical samples with different HCV-RNA levels 69
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era 69
An overview of SARS-CoV-2 variants circulating in the 2020-2022 period in Lombardy 68
Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance 68
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 68
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 68
CHARACTERISTICS OF LAMIVUDINE RESISTANCE PROFILES IN HBV REVERSE TRANSCRIPTASE FROM A NATIONAL COLLABORATIVE STUDY OF HIV plus HBV INFECTED INDIVIDUALS ON LONG-EXPOSURE TO LAMIVUDINE INCLUDING REGIMENS 68
Biphasic kinetics of HCV-RNA decay and quasispecies evolution during DAA-treatment are associated with risk of virological failure 67
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality 66
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety 66
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 65
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 65
CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING 65
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine 65
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 64
Resistance to direct-acting antiviral agents: clinical utility and significance 64
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 64
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution 63
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? 63
The use of human immunodeficiency virus resistance tests in clinical practice 62
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents 62
Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies 62
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 61
Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release 61
Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification 61
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 61
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 61
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users 60
Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy 60
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV QUANTIFICATION WITHIN BLOOD AND LIVER SAMPLES (TUMORAL AND NON TUMORAL TISSUES) OF HCC/TRANSPLANTED PATIENTS 59
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C 59
KEY PATTERNS OF HBsAg MUTATIONS CORRELATE WITH MECHANISMS UNDERLYING LEVELS OF SERUM HBV DNA 59
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 59
HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION 58
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology 58
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics 57
Early detection of NS3-resistance in HCV patients with advanced disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing 57
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population 57
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 57
Increase in invasive group A streptococcal infections in Milan, Italy: a genomic and clinical characterization 57
KEY PATTERNS OF HBX AND PRE-S1/S2 MUTATIONS ARE INVOLVED IN MECHANISMS UNDERLYING HBV-INDUCED HEPATOCELLULAR CARCINOMA IN VIVO 56
KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE 56
High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction 56
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 56
Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients 55
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 55
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 55
Totale 7.935
Categoria #
all - tutte 58.581
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.581


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022103 0 0 0 3 1 0 1 2 6 4 77 9
2022/20231.183 149 15 97 120 79 103 0 129 220 101 161 9
2023/20241.148 77 121 258 82 45 175 70 64 16 36 98 106
2024/20251.508 27 4 6 38 28 181 64 75 289 379 183 234
2025/20265.038 585 504 761 388 174 265 1.241 168 211 241 204 296
2026/20271.289 201 250 673 165 0 0 0 0 0 0 0 0
Totale 10.293